Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685834 | 0.80 | ADORA2B (0.45) | ADORA2BADORA2AADORA1ADORA3ALK | |
| SCHEMBL1720327 | 0.76 | EGFR (0.38) | ADORA2BADORA2AADORA3CDK2RPS6KA3 | |
| SCHEMBL2327645 | 0.73 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3ALK | |
| SCHEMBL1725997 | 0.71 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL15642923 | 0.70 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL27063234 | 0.69 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL23432112 | 0.66 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL14618918 | 0.65 | ADORA2B (0.47) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL30012217 | 0.65 | ADORA2B (0.71) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL13247840 | 0.65 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012154340-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |